Kiniksa Pharmaceuticals (KNSA) to Release Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) will likely be announcing its earnings results before the market opens on Tuesday, April 22nd. Analysts expect the company to announce earnings of $0.06 per share for the quarter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). The firm had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. Kiniksa Pharmaceuticals's revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter last year, the business posted $0.35 EPS. On average, analysts expect Kiniksa Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kiniksa Pharmaceuticals Price Performance

KNSA traded down $0.32 during trading on Friday, hitting $20.21. The stock had a trading volume of 529,238 shares, compared to its average volume of 463,295. The company has a 50 day moving average price of $21.05 and a 200-day moving average price of $21.47. Kiniksa Pharmaceuticals has a one year low of $16.87 and a one year high of $28.15. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -144.35 and a beta of 0.31.

Wall Street Analyst Weigh In

KNSA has been the topic of several research reports. Wedbush restated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $37.17.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 11,464 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $23.10, for a total transaction of $264,818.40. Following the completion of the sale, the chief financial officer now directly owns 23,382 shares in the company, valued at $540,124.20. This represents a 32.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, April 14th. The shares were sold at an average price of $20.48, for a total value of $245,760.00. Following the completion of the transaction, the chief operating officer now owns 77,363 shares in the company, valued at approximately $1,584,394.24. The trade was a 13.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 91,766 shares of company stock valued at $2,002,135 over the last quarter. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.